Theralase(r) closes $can 1.2 million non-brokered private placement

Toronto, on / accesswire / february 5, 2024 / theralase® technologies inc. ("theralase®" or the "company") (tsxv:tlt)(otcqb:tltff), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated photo dynamic compounds ("pdcs") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement offering ("offering") of units ("units"). on closing, the corporation issued an aggregate of 6,666,670 units at a price of $can 0.18 per unit for aggregate gross proceeds of approximately $can 1,200,000.
CAN Ratings Summary
CAN Quant Ranking